In all SCs, treatment with MDS leads to a decrease of α-SMA (immunoblotting) and the reduction of α-SMA-positive stress fibers (immunofluorescence) compared to BS (Figures 7A–C). The gene discussed is ACTA1; the disease is myelodysplastic syndrome.